Could an antibody stop Alzheimer's before it starts?

NCT ID NCT07717411

Not yet recruiting Prevention Sponsor: Hoffmann-La Roche Source: ClinicalTrials.gov ↗

First seen Jul 21, 2026 · Last updated Jul 22, 2026 · Updated 1 time

Summary

This study tests whether the experimental drug trontinemab can prevent or delay memory loss and dementia in people who have early biological signs of Alzheimer's but no cognitive symptoms. Participants receive either trontinemab or a placebo intravenously for several years. The goal is to see if the drug can keep them from progressing to mild cognitive impairment or dementia.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: an experimental antibody drug called trontinemab
What this could lead to: If successful, this could lead to the first treatment that delays or prevents the onset of Alzheimer's symptoms in high-risk individuals.
What could go wrong: This is an early-stage prevention trial, so the drug may not slow progression or could cause side effects like brain swelling. Results will take years.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALZHEIMER'S DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALZHEIMER'S DISEASE

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.